Logo
x

Search

Subscribe Now

novartis

Novartis Reports the US FDA’s Approval of Fabhalta (Iptacopan) to Treat C3 glomerulopathy

Novartis Reports the US FDA’s Approval of Fabhalta (Iptacopan) to Treat C3 glomerulopathy

  • March 21, 2025
Novartis Reports P-III (STEER & STRENGTH) trials data of OAV101 IT for Spinal Muscular Atrophy

Novartis Reports P-III (STEER & STRENGTH) trials data of OAV101 IT for Spinal Muscular Atrophy

  • March 20, 2025
Novartis to Acquire Anthos Therapeutics for ~$3.1B

Novartis to Acquire Anthos Therapeutics for ~$3.1B

  • February 11, 2025
Novartis Reports Data from P-III (STEER) Study of Onasemnogene Abeparvovec to Treat Children and Young Adults with Spinal Muscular Atrophy (SMA)

Novartis Reports Data from P-III (STEER) Study of Onasemnogene Abeparvovec to Treat Children and Young Adults with Spinal Muscular...

  • December 30, 2024
Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer

Novartis Reports Longer-Term Results from P-III (NATALEE) Trial of Kisqali (Ribociclib) to Treat Early Breast Cancer

  • December 11, 2024
Novartis’ Kisqali (Ribociclib) Secures EC’s Approval as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer

Novartis’ Kisqali (Ribociclib) Secures EC’s Approval as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer

  • November 27, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.